The LGALS1 (Galectin-1) antibody targets a protein encoded by the LGALS1 gene, a member of the galectin family involved in modulating cell-cell and cell-matrix interactions. Galectin-1. a β-galactoside-binding lectin, plays dual roles in immune regulation and cancer progression. It promotes T-cell apoptosis and immune tolerance by binding to glycoproteins on immune cells, making it a potential immune checkpoint molecule. In tumor microenvironments, LGALS1 is often overexpressed, facilitating angiogenesis, metastasis, and immunosuppression. Antibodies against LGALS1 are valuable tools for studying its expression patterns in cancers (e.g., glioblastoma, melanoma), inflammatory diseases, and neural tissues via techniques like immunohistochemistry, Western blotting, or flow cytometry. Recent therapeutic strategies explore blocking LGALS1 to counteract immune evasion or sensitize tumors to immunotherapy. However, its pleiotropic functions—including roles in neuroprotection and tissue repair—warrant context-specific evaluation. Commercial LGALS1 antibodies are typically validated for specificity using knockout cell lines or competitive assays. Ongoing research aims to clarify its isoform-specific interactions and clinical relevance as a biomarker or therapeutic target.